Publicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (18)

2025

  1. C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function

    Journal of Hematology and Oncology, Vol. 18, Núm. 1

  2. Deletion of C3G in hepatocytes impairs full liver maturation and alters glucose homeostasis

    Cell Death and Disease, Vol. 16, Núm. 1

  3. Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk

    British Journal of Haematology, Vol. 207, Núm. 4, pp. 1565-1577

  4. Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response

    Journal of Pathology, Vol. 265, Núm. 4, pp. 502-517

2024

  1. Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

2022

  1. C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

    International journal of biological sciences, Vol. 18, Núm. 15, pp. 5873-5884

  2. New functions of C3G in platelet biology: Contribution to ischemia-induced angiogenesis, tumor metastasis and TPO clearance

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells

    Cell Death and Disease, Vol. 12, Núm. 4

  2. C3G protein, a new player in glioblastoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 18

  3. Contribution of c3g and other gefs to liver cancer development and progression

    Hepatoma Research, Vol. 7

2020

  1. C3G is upregulated in hepatocarcinoma, contributing to tumor growth and progression and to HGF/MET pathway activation

    Cancers, Vol. 12, Núm. 8, pp. 1-22

  2. Coste de eltrombopag y rituximab por paciente respondedor al tratamiento de la trombocitopenia inmune primaria en España

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 44, Núm. 6, pp. 279-287

2019

  1. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

2018

  1. C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation

    Cell Communication and Signaling, Vol. 16, Núm. 1

  2. How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma

    HEPATIC ONCOLOGY, Vol. 5, Núm. 1

2017

  1. C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis

    Oncotarget, Vol. 8, Núm. 67, pp. 110994-111011

2016

  1. C3G knock-down enhances migration and invasion by increasing Rap1-mediated p38α activation, while it impairs tumor growth through p38α-independent mechanisms

    Oncotarget, Vol. 7, Núm. 29, pp. 45060-45078

2015

  1. p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: Role in migration and invasion

    Journal of Biological Chemistry, Vol. 290, Núm. 7, pp. 4383-4397